Shefali Agarwal - Aug 16, 2021 Form 4 Insider Report for Epizyme, Inc. (EPZM)

Role
Executive Vice President, Chief Medical and Development Officer
Signature
/s/ John Weidenbruch, attorney-in-fact
Stock symbol
EPZM
Transactions as of
Aug 16, 2021
Transactions value $
$0
Form type
4
Date filed
8/18/2021, 08:00 AM
Previous filing
Nov 19, 2021
Next filing
Dec 7, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EPZM Common Stock, par value $0.0001 Award $0 +59.2K +56.7% $0.00 164K Aug 16, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EPZM Stock Option (Right to Buy) Award $0 +282K $0.00 282K Aug 16, 2021 Common Stock 282K $5.31 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of shares of Common Stock issuable under 59,166 restricted stock units ("RSUs") granted pursuant to the Company's 2013 Stock Incentive Plan. Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in three equal annual installments over three years from the grant date, with the first installment vesting on August 16, 2022.
F2 This option was granted on August 16, 2021 pursuant to the Company's 2013 Stock Incentive Plan with respect to 282,270 shares of Common Stock, with 33.33% vesting on August 16, 2022 and the remaining 66.67% vesting in 24 substantially equal monthly installments thereafter.

Remarks:

Executive Vice President, Chief Medical and Development Officer